SLC13A3

Across TCGA pan-cancer cohorts, SLC13A3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC13A3 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher SLC13A3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC13A3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LGG, BLCA, and PRAD are the cancer types where SLC13A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
BLCA	DFS	Median	IV	0.083	0.476	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.959	0.627	.025	4	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC13A3–LGG (DFS)

Open the LGG breakdown →